suma/抗抑郁药

FIELD OF THE INVENTION The heterocyclic carbon compounds with which the present invention is concerned are piperazines having an additional pyridine ring which is part of a bicyclo ring system (Class 544, subclass 362). It is also concerned with drug bio-affecting and body-treating processes

The invention relates to new indole derivatives to processes for preparing them and to pharmaceutical compositions containing them. In United Kingdom patent specification No. 1,425,354, which corresponds to U.S. Application Ser. No. 597,841, filed July 21, 1975, of Archibald et al, is described and

This invention relates to ergoline derivatives, their production and pharmaceutical compositions containing them. The present invention provides compounds of formula I ##STR2## wherein R.sub.1 is n-propyl, R.sub.2 is hydrogen or alkyl(C.sub.1-3), R.sub.3 is alkyl(C.sub.1-3), and R.sub.4 is hydrogen

BACKGROUND OF THE INVENTION Drugs useful in the treatment of mental depression and apathy have generally fallen within at least one of three categories: (1) blockers of synaptosomal uptake of norepinephrine; (2) monoamine oxidase inhibitors; and (3) psychomotor stimulants. Serotonin, like

The present invention relates to the use of secondary 2-aminoalkyl-5-pyridonals of the general formula I ##STR2## wherein R is hydrogen or lower alkyl, m is an integer from 2 to 4, and n is an integer from 1 to 7, or of therapeutically useful acid addition salts thereof, as effective nootropic and

BACKGROUND OF THE INVENTION FIELD OF THE INVENTION This invention is concerned with new pharmaceutical formulations for the treatment of depressed warm-blooded animals, including man, containing as active ingredient a compound of the Formula III: ##STR3## wherein A is a group selected from

OBJECTS OF THE INVENTION It is an object of the invention to provide the novel compounds of formula I and their non-toxic, pharmaceutically acceptable acid addition salts and a novel process for their preparation. It is another object of the invention to provide novel antidepressant and neuroleptic

BACKGROUND OF THE INVENTION Major depressive disorder affects an estimated 340 million people worldwide. According to the World Health Organization, depression is the fourth greatest public health problem. If left untreated, the effects of depression can be devastating, robbing people of the energy

BACKGROUND OF THE INVENTION Major depressive disorder affects an estimated 340 million people worldwide. According to the World Health Organization, depression is the fourth greatest public health problem. If left untreated, the effects of depression can be devastating, robbing people of the energy

BACKGROUND OF THE INVENTION Major depressive disorder affects an estimated 340 million people worldwide. According to the World Health Organization, depression is the fourth greatest public health problem. If left untreated, the effects of depression can be devastating, robbing people of the energy

The present invention relates to substituted diphenyl sulfides which are useful in the treatment of mammals such as mice, dogs, rats or humans (man) suffering from a depressed state or condition. In particular the present invention is directed to compounds represented by the formula I ##STR4## or an

CROSS REFERENCE TO RELATED APPLICATIONS This application is the national stage of Application No. PCT/EP03/50374, filed Aug. 12, 2003, which application claims priority from EP Patent Application No. 02078322.1 filed Aug. 12, 2002. The invention concerns substituted tricyclic isoxazoline

FIELD OF THE INVENTION The present invention relates to a new 1-(acetyl-aminophenyl)-2-aminopropanone derivatives. It also relates firstly to the use of these new derivatives in therapy, especially as antidepressants for the central nervous system (CNS), and secondly to the method for their

CROSS REFERENCE TO RELATED APPLICATIONS This application is the national stage of Application No. PCT/EP03/50377, filed Aug. 13, 2003, which application claims priority from EP Patent Application No. 02078373.4 filed Aug. 15, 2002. The invention concerns fused heterocyclic isoxazoline derivatives,

FIELD OF THE INVENTION The present invention relates to new 1-(acetyl-aminophenyl)-2-aminopropanone derivatives. It also relates firstly to the use of these new derivatives in therapy, especially as antidepressants for the central nervous system (CNS), and secondly to the method for their